NCT01294826: Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer |
|
|
| Completed | 1 | 20 | US | AUY922, Cetuximab | Swedish Medical Center, Novartis Pharmaceuticals | Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/15 | 05/15 | | |
